MIDDLE EAST AND TURKEY HEMOPHILIA TREATMENT MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Middle East and Turkey Hemophilia Treatment Market - Overview Middle East and Turkey Hemophilia Treatment Market by Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East) is estimated to be valued at US$ 645.1 million in 2019, and is expected to exhibit a CAGR of 4.2%, during the forecast period (2019-2027). Middle East and Turkey hemophilia treatment market is expected to witness significant growth, owing to increasing adoption of collaborations and acquisitions strategies by market players and rising initiatives by governments and market players to offer cost-effective hemophilia treatment. For instance, in February 2019, F. Hoffmann-La Roche AG participated in World Federation of Hemophilia (WFH) Humanitarian Aid Program and donated Hemlibra to 1,000 patients suffering from hemophilia A in emerging economies. Browse 21 Market Data Tables and 20 Figures spread through 185 Pages and in-depth TOC on " Middle East and Turkey Hemophilia Treatment Market, by Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East) - Global Forecast to 2027" Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/middleeast-and-turkey-hemophilia-treatment-market-3250 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Several key players in the market are focused on receiving approval for their novel products and launching them into the market. Approval and launches of such novel products in the market is expected to create a lucrative environment for growth of Middle East and Turkey hemophilia treatment market over the forecast period. For instance in June 2019, Novo Nordisk received marketing authorization from European commission for Esperoct in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency) In April 2019, Roche Products India Pvt Ltd launched its hemophilia A drug emicizumab, branded as Hemlibra in India. It is indicated as a prophylactic treatment for reducing the frequency of bleeding episodes in patients with hemophilia A, through Factor VIII inhibitors. Key players are focused on development of novel drug delivery therapy for treatment of hemophilia, and this is expected to create a lucrative opportunity for key players to provide advance drug delivery system. For instance, in 2016, researchers from the Cockrell School of Engineering at The University of Texas, Austin, developed biodegradable delivery system, A capsule for people suffering from Factor VIII deficiency. It contains micro and nanoparticles, to carry a protein therapy that treats hemophilia. Increasing clinical trials by key players on hemophilia treatment is expected to drive the Middle East and Turkey hemophilia treatment market growth over the forecast period. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/3250 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Key Takeaways of the Middle East and Turkey Hemophilia Treatment Market: The Middle East and Turkey hemophilia treatment market is expected to exhibit a CAGR of 4.2% during the forecast period (2019-2027), owing to increasing product launches for treating hemophilia by key players. For instance, in May 2018, Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche Group, launched its anti-coagulation factor IXa/X humanized biospecific monoclonal antibody/coagulation factor VIII substitute, HEMLIBRA for routine prophylaxis, to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors. For instance, in February 2019, Takeda Pharmaceutical Company Limited announced results from its phase IIIb/IV clinical trial for ADYNOVATE, a recombinant antihemophilic factor at the 12th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD), Prague, Czech Republic.
Major players operating in the Middle East and Turkey hemophilia treatment market include Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3250 Š Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
Š Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
Š Coherent market Insights. All Rights Reserved